Medunik

Medunik USA, founded in 2014 and launched commercially in 2017, is a private, commercial-stage biopharmaceutical company specializing in providing orphan drugs for rare diseases in the United States. As a strategic subsidiary of Canada's Duchesnay Pharmaceutical Group, it leverages international partnerships to identify, secure U.S. approval for, and ensure the continuous supply of rare disease therapeutics. The company's mission centers on bridging treatment gaps for underserved patient populations, with an initial focus on hematology and urea cycle disorders, while adhering to high standards of compliance and ethical responsibility.

Partnership-driven model for identifying, developing (for U.S. regulatory approval), and commercializing existing orphan drugs from other markets for the U.S. Focus on regulatory strategy, supply chain resilience (reshoring/nearshoring), and specialized rare disease market access.

Medunik competes with other specialty pharma companies focused on rare diseases, such as Horizon Therapeutics (now Amgen), Alexion (now AstraZeneca), and BioMarin, as well as larger pharma companies with orphan drug divisions. Its differentiation lies in its specific model of sourcing non-U.S. approved drugs and its operational focus on supply chain security within the Duchesnay group ecosystem.